JACOBS LEVY EQUITY MANAGEMENT, INC
Position in FTRE — Fortrea Holdings Inc.
CIK 884414
FLORHAM PARK, NJ
Position in FTRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,168,007
+$4,469,848 QoQ
Shares Held
526,897
+5.6% QoQ
Ownership
0.554%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#37
of 334 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 80%
Shared 0%
None 20%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $740,535,030 across 80 Biotechnology names. FTRE ranks #17 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
256,503 | $159,939,880 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,939,719 | $98,157,217 | |
| 3 | INCY |
Incyte Corp
|
731,774 | $82,953,900 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
695,532 | $60,476,507 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
322,377 | $25,232,447 | |
| 6 | EXEL |
Exelixis, Inc.
|
415,650 | $22,615,516 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,231,516 | $20,898,826 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
60,986 | $18,358,615 |
All Filings in FTRE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,168,007 | 526,897 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $4,698,159 | 498,743 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $905,764 | 107,573 | Shares | Sole | 2025-11-17 | |
| 2024-12-31 | $16,069,679 | 861,645 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $22,712,380 | 1,135,619 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $21,204,623 | 908,510 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $630,358 | 15,704 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||